Abstract Body

Viral suppression (VS) among HIV-positive individuals is essential for protecting health and preventing new infections. Financial incentives (FI) have shown promise in modifying health behavior in low-income countries but few studies have assessed whether they can increase the likelihood of VS.

Antiretroviral therapy (ART) eligible HIV-positive adults diagnosed at community health campaigns (CHCs) or at a rural clinic in Uganda were randomized to receive FI for achieving VS (viral load<400 copies/mL) at 6, 12, and 24 weeks or to a control group with no FI (NCT02890459). Viral load (VL) was measured at baseline, 6, 12, and 24 weeks; results were disclosed to all participants. At each interval, FI amounts rose from 15,000-45,000 Uganda Shillings (US$4–12.50) with a reset contingency if VS was not achieved. The primary outcome was VS at 24 weeks. The proportions achieving VS in intervention and control groups were compared using chi-squared tests. Intention-to-treat (ITT) analyses and per-protocol analyses were performed for participants enrolled at least 24 weeks prior to August 31, 2017.

From June 2016-May 2017, 400 adults were enrolled (CHCs: 382, clinic: 18), 12 (3%) withdrew before 24 weeks, and 383 (96%) completed 24 weeks by August 31, 2017. Participants’ mean age was 38 years, 57% were women, and median daily income was US$0.86. At baseline, the mean CD4 count among participants was 557 cells/μL and 76% had VL<400 copies/ml. In ITT analyses, 8% of participants in both groups did not have a 24-week VL measure and were considered unsuppressed. There was a trend towards higher VS at 6 weeks in the intervention group (83%) than the control group (76%, p=0.09). However, there was no significant difference between intervention and control groups in proportion achieving VS at 24 weeks (85% vs. 82%, p=0.42). Likewise, incentives had no effect among those not suppressed at baseline, with 60% and 53% achieving 24-week VS in the intervention and control group, respectively (p=0.55). Per-protocol analyses among 351 participants with 24-week VL measures showed no difference in VS, as 90% and 92% achieved VS in both groups (p=0.67).

Over a six-month period, FI had no effect on VS rates among HIV-positive ART eligible adults. Provision of VL results to the control group and high baseline VS may have contributed to high rates of VS in both study groups, and incentives may have been provided too infrequently to influence daily medication adherence.